Last $0.52 USD
Change Today +0.02 / 4.00%
Volume 2.0K
GIDYL On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

gi dynamics inc-cdi (GIDYL) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/16/13 - $1.03
52 Week Low
04/11/14 - $0.47
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GI DYNAMICS INC-CDI (GIDYL)

Related News

No related news articles were found.

gi dynamics inc-cdi (GIDYL) Related Businessweek News

No Related Businessweek News Found

gi dynamics inc-cdi (GIDYL) Details

GI Dynamics, Inc. designs, develops, and markets medical devices for non-surgical approaches in the United States. It offers EndoBarrier, a non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. The company sells its product in Europe, South America, and Australia. GI Dynamics, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.

72 Employees
Last Reported Date: 07/3/14
Founded in 2003

gi dynamics inc-cdi (GIDYL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $416.7K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $298.1K
Chief Medical Officer
Total Annual Compensation: $220.0K
Compensation as of Fiscal Year 2013.

gi dynamics inc-cdi (GIDYL) Key Developments

GI Dynamics, Inc. Provides Revenue Guidance for the Second Quarter of 2014

GI Dynamics, Inc. provided revenue guidance for the second quarter of 2014. For the second quarter, preliminary revenues are estimated to be slightly below first quarter 2014, in part due to less than expected sales in Chile, as well as delayed regulatory approval in Brazil.

GI Dynamics, Inc. Announces the Resignation of Mark C. Twyman as Chief Commercial Officer, Effective July 2, 2014

GI Dynamics, Inc. announced that Mark C. Twyman is leaving his position as chief commercial officer, effective July 2, 2014.

GI Dynamics, Inc. Announces New Findings for Elimination of and Reduced Reliance on Insulin by Patients Treated with Endobarrier(R) Therapy

GI Dynamics, Inc. announced new findings that EndoBarrier(R) Therapy enabled a rapid reduction in, and elimination of, insulin therapy by patients with type 2 diabetes and obesity. These findings from a retrospective analysis of 100 patients in Australia were presented at the American Association for Clinical Endocrinology 23 Annual Meeting and Scientific Congress in Las Vegas, Nevada. The retrospective analysis reviewed the medical records and nationwide patient registry of the first 100 patients in Australia who received EndoBarrier Therapy. Of these 100 patients, 11 required the use of insulin to manage their type 2 diabetes prior to receiving EndoBarrier Therapy. Following placement of the EndoBarrier, there was an overall lowering of insulin requirements based on the protocol at the two treatment centers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GIDYL:US $0.52 USD +0.02

GIDYL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GIDYL.
View Industry Companies

Industry Analysis


Industry Average

Valuation GIDYL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 74.4x
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GI DYNAMICS INC-CDI, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at